Equity Details
Price & Market Data
Price: $7.16
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $6,052,109,824
Daily Volume: 0
Performance Metrics
1 Week: 3.77%
1 Month: 21.36%
3 Months: 14.93%
6 Months: -0.97%
1 Year: 40.50%
YTD: 4.83%
About H. Lundbeck A/S (HLBBF)
Essential market data for H. Lundbeck A/S (HLBBF). The stock is trading at 7.16, with a daily change of $0.00 / 0.00%. Market cap: 6,052,109,824. Review its performance across all major time intervals.
Company Details
Employees: 5214
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Denmark
Details
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.